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 Detection of newly emerging psychoactive
substances using Raman spectroscopy and
chemometrics†
Jesus Calvo-Castro, ‡ Amira Guirguis, ‡ Eleftherios G. Samaras, Mire Zloh,
Stewart B. Kirton * and Jacqueline L. Stair*
A novel approach for the identiﬁcation of New Psychoactive Substances (NPS) by means of Raman
spectroscopy coupled with Principal Components Analysis (PCA) employing the largest dataset of NPS
reference materials to date is reported here. Fifty three NPS were selected as a structurally diverse subset
from an original dataset of 478 NPS compounds. The Raman spectral proﬁles were experimentally
acquired for all 53 substances, evaluated using a number of pre-processing techniques, and used to
generate a PCA model. The optimum model system used a relatively narrow spectral range (1300–
1750 cm1) and accounted for 37% of the variance in the dataset using the ﬁrst three principal
components, despite the large structural diversity inherent in the NPS subset. Nonetheless, structurally
similar NPS (i.e., the synthetic cannabinoids FDU-PB-22 & NM-2201) grouped together in the PCA model
based on their Raman spectral proﬁles, while NPS with diﬀerent chemical scaﬀolds (i.e., the
benzodiazepine ﬂubromazolam and the cathinone a-PBT) were well delineated, occupying markedly
diﬀerent areas of the three-dimensional scores plot. Classiﬁcation of NPS based on their Raman spectra
(i.e., chemical scaﬀolds) using the PCA model was further investigated. NPS that were present in the
initial dataset of 478 NPS but were not part of the selected 53 training set (validation set) were observed
to be closely aligned to structurally similar NPS within the generated model system in all cases.
Furthermore, NPS that were not present in the original dataset of 478 NPS (test set) were also shown to
group as expected in the model (i.e., methamphetamine and N-ethylamphetamine). This indicates that,
for the ﬁrst time, a model system can be applied to potential ‘unknown’ psychoactive substances, which
are new to the market and absent from existing chemical libraries, to identify key structural features to
make a preliminary classiﬁcation. Consequently, it is anticipated that this study will be of interest to the
broad scientiﬁc audience working with large structurally diverse chemical datasets and particularly to law
enforcement agencies and associated scientiﬁc analytical bodies worldwide investigating the
development of novel identiﬁcation methodologies for psychoactive substances.
Introduction
The market for New Psychoactive Substances (NPS) has been
characterised by its huge variety and diversity. In the last decade
there has been an increasingly large and rapid appearance of
newly emerging drugs, with more than 700 currently moni-
tored.1–3 In most cases, this can be attributed to eﬀorts by
suppliers to evade their detection and circumvent existing
legislation.1,4 This rapid appearance, poor detectability,
increased potency and availability of newly emerging drugs is
oen accompanied by an increase in reported health harms,
emergency department visits and even fatalities, making NPS
a major public health concern.1,2 In an attempt to restrict the
production, supply and abuse of NPS, countries such as New
Zealand, andmore recently the United Kingdom, have approved
psychoactive substances Acts, oen referred to as ‘blanket
bans’.5,6 Current NPS legislation however represents an even
greater challenge for law enforcement units and associated
scientic bodies trying to develop more eﬃcient, sensitive and
selective detection methodologies, particularly for the front line
(i.e. customs), that could possibly match the rapid and contin-
uous surge of newly abused substances.
To date, the majority of spectroscopic and chromatographic
analytical techniques employed in the detection of NPS rely on,
and are restricted to, reference standard availability.1 This oen
precludes the application of such approaches to the identica-
tion of newly appearing substances, which is crucial in reducing
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the potential harms caused by NPS. Subsequently, eﬀorts have
been devoted to the development of selective and sensitive
detection methodologies that build upon the modulation of
analyte response.1,7–9 However, it is acknowledged that such
approaches are currently limited to a discrete number of
traditional drugs of abuse or well established NPS, requiring
time-consuming development and optimisation of techniques
for each new substance. Accordingly, there remains a need for
more universal in-eld identication methodologies that can
not only eﬀectively identify existing NPS substances, but more
importantly be applicable for newly emerging drugs. To address
these shortcomings, a number of studies have engaged in the
rational design and realisation of novel methodologies and
algorithms for the in-eld detection of NPS.8,10–19 Along these
lines, a number of vibrational spectroscopy techniques (i.e. IR,
NIR and Raman) which can be realised in portable, handheld
instruments have been successfully utilised for the in-eld
identication of NPS. Among these, Raman spectroscopy
shows great potential due to desirable properties such as non-
contact/non-destructive analysis; and low sensitivity to cutting
agents/adulterants, moisture and the physical properties of the
sample.18,20–24
An added complexity in the development of novel
approaches for the identication of NPS arises from the fact
that existing NPS are oen classied using a pragmatic
approach (i.e., based on pharmacological activity,25,26 chemical
structure, etc.), which causes diﬃculty in interpreting the
control status of an NPS. Also, NPS classication is constantly
being modied and changed based on popularity, current
trends, new evidence and legislation.15,27 As a result, our recent
work28 attempts to address the existing issues with regards to
the classication of NPS, where a dataset of 478 NPS was
systematically categorised according to their chemical struc-
tural features. Using a soware based on a technique called
hierarchical clustering, the NPS investigated were divided into
21 categories based on all compounds in the category sharing
a common structural core referred to as the maximum common
substructure (MCS).27 These top-level categories were broken
down further into 79 subcategories (13 of which contained only
a single molecule i.e. compounds that were signicantly struc-
turally distinct from all other known NPS, also referred to as
singletons). As such, it was hypothesised an adequately selected
subset of NPS compounds could be used to represent the entire
structural diversity of the dataset (478 NPS) and that further-
more, this subset could aid in the identication and/or
prediction of key structural features of both known and newly
emerging NPS.
Thus, the aim of this study was to develop a model that can
be used to identify chemical structural features of NPS,
including newly emerging NPS, using Raman spectral proles
and Principal Component Analysis (PCA).
Experimental
Selection of training, validation and test set
In our previous work,28 79 NPS were identied as representa-
tives of the chemical space inherent in the 478 NPS dataset.
Fiy-three (SI.1†) of these 79 NPS were selected and purchased
to be used as the training set following the exclusion of
singletons (i.e., a molecule that did not share signicant
structural similarity with any other NPS in the chemical space
studied) and availability. An additional 21 NPS were used to
further validate and test the generated model. These were split
into two diﬀerent groups, the validation set (17) and test set (4),
where validation set NPS (SI.2†) were compounds that were part
of the initial 478 compound dataset but not used as training set,
and test set substances, that were psychoactive drugs external to
the initial dataset of 478 compounds (SI.3†).
Dissimilarity calculations
Structural similarity between all NPS investigated in this work
was quantied by calculating the pairwise dissimilarity values
(i.e. 1 – tanimoto similarity value, determined from a chemical
ngerprint) using the ChemAxon JChem soware suite.29
New psychoactive substances
Reference standard materials (purity $ 98%) for training, vali-
dation and test sets were purchased in powder form from Chi-
ron AS (Trondheim, Norway) and LGC Group (Teddington, UK)
in all cases unless otherwise stated and used as supplied.
Controlled substances were purchased under UK Home Oﬃce
License.
Raman spectroscopy
Raman analyses were carried out utilising a benchtop Renishaw
inVia Raman microscope equipped with a high sensitivity ultra-
low noise RenCam CCDC detector and ultra-high precision
diﬀraction grating of 1200 lines per mm. The instrument was
operated using the WiRE soware supplied by the manufac-
turer. All reported spectra were measured employing a 785 nm
excitation wavelength with ca 5.8 mW power at sample. NPS
standards were analysed on Al plates and interrogated a total of
10 times focusing on diﬀerent regions of the powder to account
for anisotropic eﬀects.
Subsequently, the experimentally acquired Raman spectra
(100–3200 cm1) were pre-processed prior to multivariate
analysis. Spectra were smoothed, and baseline subtracted by
means of the Savitzky–Golay algorithm as implemented in
OriginPro 2016 soware to reduce shot/residual noise and
raised baseline respectively. Maximum normalisation was then
applied to each spectrum individually.
Principal component analysis
Pre-processed Raman spectra were initially critically assessed
using PCA, a multivariate technique that has previously been
employed in the analysis of spectroscopic data.16,30–32 For this
study, the NIPALS (Non-linear Iterative Projections by Alternating
Least Squares) algorithm was implemented in the Unscrambler X
10.4 soware (CAMO, Oslo, Norway). Each generated model was
full crossed validated (one sample per segment). Validation and
test-set representatives were tested against the generated model
system by means of projection PCA.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 31924–31933 | 31925
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Results and discussion
Three-dimensional model system using NPS training set
In order to develop a model system, the Raman spectra of the
NPS training set were examined using PCA. Given the large size
of data matrix (530 spectra  3642 variables), a systematic step-
wise data reduction methodology was explored to identify the
optimum spectral region of interest whilst maximising the
amount of explained variance, particularly by the rst three
principal components. In short, it was observed that a decrease
in the number of spectral replicates from 10 to 5, then 3 and
nally 1 had a negative impact with respect to the model
robustness. In turn, a systematic and rational selection of
spectral regions of interest underpinned by the in-depth anal-
ysis of line loading plots for the generated PCA models resulted
in a consistent improvement in the amount of explained vari-
ance for the dataset (i.e., 11/9/6 and 16/12/9% explained vari-
ance for PC1/PC2/PC3 using the 250–3200 and 1300–1750 cm1
spectral ranges respectively).
A PCA model system was developed (Fig. 1) comprising 10
replicate spectra for each of the (53) NPS in the training set and
a narrow33 spectral region of interest (from 1300 to 1750 cm1),
that still contained the majority of the spectral information for
all investigated NPS and yielded the largest explained variance
from all investigated spectral regions (vide supra). Moreover, the
optimised model accounted for 37% of the variance using the
rst three principal components. This arguably low amount of
explained variance can be attributed to the intrinsic chemical
diversity of the training set, a selected subset of 53 representa-
tives from a dataset of 478 NPS. Nevertheless, as illustrated in
Fig. 1, it is important to note the discriminative ability of the
generated model. NPS previously shown to assemble together in
hierarchical clustering experiments28 based on chemical
connectivity (Categories 1–13), largely group together and
furthermore occupy distinctly diﬀerent areas of the three-
dimensional scores plot with respect to Raman active chem-
ical scaﬀolds. Again, the structural similarity between NPS in
the training set drawn from each diﬀerent structural category
can be seen in SI.1.† Examination of diﬀerent regions of the
scores plot arising from generating the PCA model will be dis-
cussed further below by focusing on particular categories of
compounds from Fig. 1.
Fig. 2 shows Category 1 compound data whose members
share an indole core (depicted in black on the chemical struc-
ture) isolated with example spectra. Via judicious analysis of the
three-dimensional scores plot, it was observed that training set
NPS bearing indole cores occupy two distinct regions, primarily
delineated by PC2, which agrees with current pragmatic clas-
sications.2 For example, the compounds FDU-PB-22 and NM-
2201 group together and are known synthetic cannabinoids,
whilst 5-MeO-DALT, 5-MeO-MiPT and 4-HO-DET group together
in a diﬀerent area of the scores plot and are known tryptamines
(Fig. 2).
This nding can be ascribed to the diﬀerent substitution
patterns on position 3 of the indole cores in these synthetic
cannabinoids and tryptamines, leading to distinct spectral
proles in the region of interest as illustrated in Fig. 2. The
diﬀerent locations observed on the scores plot can be further-
more accounted for by the loading plot for PC2 (grey solid line
in Fig. 2), exhibiting high loading at a vibrational frequency that
coincides with vibrational bands uniquely observed in the
Raman proles for the three tryptamines at ca. 1560 cm1 and
attributed to quadrant stretching vibrational motions of the
indole core,33,34 bearing substitution on the N atoms, which are
not present in the synthetic cannabinoids counterparts. This
example demonstrates that although all these substances share
an indole core, their specic substitution patterns were distin-
guished via their Raman prole and delineated by the PCA
scores plot. Thus, there is ability to predict not only a core
structure but also to suggest the unique substitution pattern of
Fig. 1 A three-dimensional scores plot generated using Raman spectra for the NPS training set (ten replicate spectra per substance, spectral
region: 1300–1750 cm1). Refer to SI.1† for details on the members belonging to each of the categories identiﬁed by hierarchical clustering.
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a previously ‘unknown’ NPS. Another key example in the model
system is illustrated by the compounds in Category 5. In our
previous work,28 the largest number (n ¼ 18/53) of NPS repre-
sentatives were drawn from Category 5. The large number of
compounds in this category is a result of the MCS being
a simple benzene ring. Thus, in the initial dataset of 478
compounds Category 5 contains more members than any other
category of compounds. Despite the diversity in this category
(see SI.1†), all 18 representative NPS were observed to closely
group along the two rst principal components in the PCA
model, with delineation amongst the group occurring due to
separation of the molecules along PC3 (see Fig. 1). This is
demonstrated by the only two substances belonging to the
quinazoline class in the training set; aoqualone and mebro-
qualone, (Fig. 3). The delineation of these two molecules along
PC3 can be ascribed to large similarities between the PC3
loading plot and the spectral prole of aoqualone in the region
of interest, i.e. the vibrational band associated with the carbonyl
stretching motion at ca. 1670 cm1. A higher frequency (ca.
1690 cm1) is observed for mebroqualone, which can be
attributed to an intramolecular H-bonding interaction,
precluded in aoqualone upon o-methyl substitution a diﬀer-
ence, which allows for the separation of these molecules along
PC3.
The third example is focused on Category 9, whose repre-
sentative structures are two thiophenyl containing structures
(depicted in black on the chemical structure in Fig. 4), which is
not present in the MCS of any other of the 21 categories iden-
tied by hierarchical clustering. The two substances, MPA
(arylalkylamine) and a-PBT (cathinone), were evaluated with
respect to the PCA model scores plot, and their Raman spectra.
Although these are the only two thiophenyl containing struc-
tures in the training set, a detailed understanding of Category 9
is anticipated to play a crucial role in accounting for newly
Fig. 2 Three-dimensional scores plot (left), Raman spectral proﬁle (right) (grey solid line denotes PC2 loadings) and chemical structures of
training set NPS sharing an indole core (illustrated in black on their chemical structures).
Fig. 3 Three-dimensional scores plot (left) (projections illustrated for ease of visualization), Raman spectral proﬁles (right) (grey solid line denotes
PC3 loadings) and chemical structures of the quinazoline containing structures, aﬂoqualone and mebroqualone.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 31924–31933 | 31927
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emerging NPS with a unique scaﬀold, such as thiophene-based
compounds. In the three-dimensional scores plot (Fig. 4), MPA
and a-PBT are closely grouped along PC1. In turn, clear delin-
eation between the two is achieved along PC2 and to a lesser
extent PC3. In this regard, delineation along PC2 can be readily
understood as a consequence of the high negative loading of
this principal component at ca. 1440 cm1, oen associated
with aliphatic stretching vibrational motions, which coincides
with the highest intensity vibrational band of MPA in the
selected spectral region. In addition, neither PC1 nor PC3 are
characterised by particularly high loadings that coincide with
vibrational frequencies of signicant intensity for MPA or a-
PBT, hence the lack of signicant delineation along these two
principal components is not unexpected. Thus, based on spec-
tral region selected, delineation occurs based on the function-
alities substituted on the thiophene groups (i.e. carbonyl group
present in a-PBT and absent in MPA).
Evaluation of model system using validation set NPS
The model system was then tested by using NPS from the
original 478 substance dataset28 that were not designated as
training set compounds (henceforth referred to as the “valida-
tion set”). Contrary to the training set, validation set scaﬀolds
(SI.2†) were selected to exhibit larger dissimilarity with respect
to their category medoids i.e. the members of a given category
that are structurally most similar, on average, to all other
members in that category. Dissimilarities greater than 0.200
were calculated for 10 out of 17 (59%) validation set NPS, as
opposed to 2 out of 53 (4%) for the training set,28 thus posing
a genuine challenge for the evaluation of the PCA model. It was
of interest to investigate the performance (amount of explained
variance) of the PCA model with respect to the validation set. To
achieve this, the generated model system was used to calculate
the amount of explained variance within the validation set
without altering the generated model system (i.e. via projection
of the validation set onto the PCA model). In this regard,
percentages of explained variance for the validation subset that
approach that of the training set would indicate a robust model
system able to account for newly emerging NPS. Performance of
the model, with the validation set (15/11/7% for PC1/PC2/PC3
respectively regarding the percentage of explained variance)
was comparable to that achieved by the model for the training
set (16/12/9 for PC1/PC2/PC3 respectively). Hence, the model
was considered robust and predictive.
The next step used to evaluate the performance of the model
with respect to the validation set was individual comparisons of
each substance in the validation set compared to the category
representative used in the 53-molecule training set (MCS for the
compounds in each category are shown in black). Each
substance in the validation set had a pre-determined category
designation (see SI.2†),28 which was used as the basis for
determining model success (i.e. if the model predicted the
compound to be in the same category as the pre-determined
categorisation, it was deemed successful). It was observed
that, in all cases, validation set substances were closely grouped
with structurally similar training set NPS when projected onto
the model. Key examples to demonstrate this are highlighted
below.
Due to its scaﬀold being present in a wide-range of NPS, it
was considered of particular interest to examine validation set
NPS with the phenylethylamine backbone (again illustrated in
black) from Category 2, namely 5-APB, 6-APB and bk-2C-B.
Related NPS from the training set were N-Me-2-CB and 2,5-
dimethoxy-4-methylamphetamine (DOM or STP). This allowed
for an in-depth analysis of the relative position of the validation
samples in the three-dimensional scores plot. Examination of
the three-dimensional scores plot illustrated in Fig. 5, illus-
trated close grouping of the arylalkylamines from the validation
set (5-APB and 6-APB) with STP from the validation set. This can
Fig. 4 Three-dimensional scores plot (left) (projections illustrated for ease of visualization), Raman spectral proﬁle (right) (grey solid line denotes
PC2 loadings) and chemical structures of the thiophenyl containing structures, a-PBT and MPA.
31928 | RSC Adv., 2018, 8, 31924–31933 This journal is © The Royal Society of Chemistry 2018
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be ascribed to the presence of a medium-intensity peak in all
three Raman spectra at ca. 1620 cm1 and the high loadings
registered for PC1 and PC3 in this spectral region.
In turn, greater delineation between bk-2C-B and its training
set counterpart, NMe-2C-B was illustrated, particularly along
PC3. Closer analysis shows bk-2C-B to exhibit close alignment to
one of the other phenylethylamine containing structures within
the training set, 4-MeO-a-PVP. This nding is validation for the
model system and also reinforces its discriminative power
which can be ascribed structurally to the presence of carbonyl
groups (absent in NMe-2C-B) in both bk-2C-B and 4-MeO-a-PVP,
i.e. the latter two are both cathinones. This carbonyl function-
ality is represented spectrally by a vibrational band at ca.
1650 cm1, which coincides with a region of high loading for
PC3. Therefore, we anticipate that particular functional groups
and associated substitution patterns that exhibit distinct
Raman active bands can play a crucial role in the identication
and correct classication of newly emerging NPS.
The second key example compares the popular synthetic
cannabinoid 5F-PB-22 from the validation set which is most
similar to phenyl acetates from the training set (Category 6
members). Classication of 5F-PB-22 via the PCA model system
(Fig. 6) revealed a closer alignment to its non-uorinated
training set analogue, PB-22, than to the other phenyl acetate
containing structures within the training set, namely N-PB-22,
a synthetic cannabinoid and 4-AcO-DMT, a tryptamine. PB-22
and its uorinated structural analogue, 5F-PB-22, exhibited
very close alignment in the three-dimensional scores plot along
all three principal components in line with their closely related
chemical structures and Raman spectral proles. This further
validates the strength of the model system. The Raman spectral
prole throughout the region of interest featured medium to
high intensity vibrational bands centred at ca. 1382, 1425, 1531
and 1711 cm 1. The lack of signicant spectral diﬀerences
between these two synthetic cannabinoids is ascribed to the
uorine substitution carried out on the terminal position of the
long aliphatic chain, hence precluding strong polarizability
changes that would result in distinct spectral features in the
region of 1300–1750 cm1. Along these lines, terminal halogen
substitutions have become popular strategies in the design of
novel psychoactive substances.35–37 Herein, we have demon-
strated that their negligible impact on the Raman spectral
properties facilitates their identication based on previously
existing non-halogenated analogues.
All three synthetic cannabinoids in Fig. 6, (5F-PB-22, PB-22
and N-PB-22) were observed to be closely aligned in three-
dimensional scores plot, which can be accounted for by
means of the vibrational bands at ca. 1382, 1425 and 1577 cm1
all of which are present in the Raman proles of the three
compounds and that are ascribed to vibrational motions within
their common quinoline motif.
In turn, the tryptamine, 4-AcO-DMT, bears an indole core
instead, which was observed to result in small shis to these
vibrational bands (centred at ca. 1390, 1438 and 1550 cm1).
Thus, the delineation in the three-dimensional scores plot
observed between these phenyl-acetate containing synthetic
cannabinoids and tryptamine representative, particularly along
PC1, can be accounted for on the basis of the observed PC1 high
loadings at ca. 1438 and 1550 cm1, which strikingly coincide
with strong vibrational bands of 4-AcO-DMT and absent in the
spectral prole of the three synthetic cannabinoids.
The third example selected from the validation set is the
benzodiazepine, pyrazolam, as it possesses a unique fused
herterocycle ring system. Fig. 7 looks at pyrazolam with regards
to the structurally related training set benzodiazepines (Cate-
gory 8), etizolam and ubromazolam. All three structures bear
the 3,7-dimethyl-9H-[1,2,4]triazolo[4,3-a][1,4]diazepine core
(depicted in black on the chemical structure). In most cases,
benzodiazepines include a 7-membered ring, an additional
benzene ring and an electron attracting group at position 7 of the
Fig. 5 Three-dimensional score plots (left), Raman spectral proﬁles (right) (solid grey and black lines denote PC1 and PC3 loadings respectively)
and chemical structures for training and validation set NPS bearing phenylmethanamine core.
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fused heterocyclic rings to ensure biological activity.38 Along these
lines, benzodiazepines are commonly sub-categorised according to
the functional group attached to the 7-membered ring, which may
include keto, hydroxyl, imidazo or triazolo groups. The three NPS
in Fig. 7 have a triazolo group as the functional group. In-depth
analysis of the validation set projection on the PCA model
reveals clear delineation between pyrazolam and etizolam (along
PC2 and PC3) and in turn close alignment of the validation
compound pyrazolam with ubromazolam along PC1 and PC3
and, to a lesser extent, along PC2.
Close examination of their Raman spectral proles in the
region of interest and associated line loadings reveals coin-
ciding strong Raman active bands at ca. 1440 and 1593 cm1 in
ubromazolam and pyrazolam (absent in etizolam) with high
intensity loadings along PC2 and PC3 respectively (Fig. 7).
Structurally, this can be attributed to the fused thiophene ring
which is present in etizolam and absent in its counterparts
which bear a fused benzene ring to the pyrimidine ring instead.
Thus, the pyrazolam was positioned closely in the model to the
most structurally similar benzodiazepine training structure
which provides validation, but once again reinforces the
delineation capability of the generated model system.
Evaluation of the model system using the test set
The performance of the model system was then evaluated using
‘unknown’ psychoactive substances external to the initial 478
NPS dataset (in the following denoted as test set, SI.3†). The
purpose of this section is to evaluate the model's capability to
propose chemical scaﬀolds for previously unknown substances
(i.e., unknown with respect to the dataset used to create the
initial model). To do this, the dissimilarity scores (vide supra) of
Fig. 6 Three-dimensional scores plot (left), Raman spectral proﬁle (right) (solid light grey line denote PC2 loadings) and structures for phenyl
acetate containing systems, N-PB-22, PB-22, 4-AcO-DMT (training set) and 5F-PB-22 (validation set).
Fig. 7 Three-dimensional scores plot (left), Raman spectral proﬁle (right) (solid black and grey lines denote PC3 and PC2 line loadings plots
respectively) and chemical structures for ﬂubromazolam, etizolam and pyrazolam.
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the test set compounds, namely MDMA, methamphetamine, S-
cathinone and methylphenidate, to all cluster medoids were
calculated and corresponding spectra investigated using PCA.
In this regard, it was observed that methylphenidate repre-
sents a complex scenario with a lowest dissimilarity value
(0.540) computed against training set representatives 4-MeO-
PCP, 4-MeO-a-PVP and 4-Me-N-ethylnorpentedrone, which
further illustrates the complexity posed by newly emerging NPS.
In light of this arguably high dissimilarity scores calculated for
methylphenidate, we anticipate that this derivative would have
been classied as a singleton in our original 478 NPS dataset.
Interestingly, projections of MDMA, methamphetamine and S-
cathinone on the three-dimensional scores plot (Fig. 8) exhibit
close alignment to the training set molecules that have the closest
structural similarity (or lowest dissimilarity scores) i.e., methylone
(0.190), N-ethyl-amphetamine (0.090) and mephedrone (0.170)
respectively. These ndings were further explored by the analysis
of their Raman spectral proles in the region of interest. It was
observed that the ‘pair’ exhibiting the lowest dissimilarity scores
(N-ethylamphetamine/methamphetamine) was characterised by
the closest alignment in the three-dimensional scores plot and that
furthermore, the ‘pair’ methylone/MDMA were the furthest apart
in the three-dimensional scores plot, in line with their computed
highest dissimilarity score (0.190) for these three investigated
‘pairs’. The low dissimilarity score (0.090) and close location of N-
ethylamphetamine and methamphetamine can be ascribed to
their high structural similarity, solely diﬀering in the ethyl/methyl
substitution on the nitrogen, which was accounted for in the
Raman spectra. In turn, we observed larger distances within the
pairs S-cathinone/mephedrone and methylone/MDMA, in line
with their calculated larger dissimilarity score (0.170 and 0.190
respectively).
In the case of the pair formed by S-cathinone and mephe-
drone, both synthetic cathinones, their delineation along PC3
in the three-dimensional scores plot can be ascribed to close
alignment of the peak centered at ca 1590 cm1 with a high PC3
loading. Discriminating between the diﬀerent structural
analogues of synthetic cathinones has been reported to be oen
aﬀorded by means the position of the two high intensity Raman
active bands at ca 1600 and 1700 cm1 and their relative
intensities.14,17,19,39 However, successful identication is limited
by the availability of reference standard materials in the
chemical libraries used. In addressing this limitation, it is
anticipated the ability of our generated model system in delin-
eating structural analogues of synthetic cathinones by means of
the high intensity loadings of PC1 and PC3 at ca 1600 cm1
(SI.4†).
MDMA projection is delineated with respect to its least
dissimilar training set representative (methylone) along the
third principal component. We observed this to be largely
associated to the strong vibrational peak at ca 1680 cm1 from
the carbonyl group in methylone, which is absent in MDMA and
that importantly coincides with a region of high loadings in PC3
(Fig. 8). Along these lines, it is of interest that our ndings agree
with previous reports whereby samples containing MDMA were
diﬀerentiated from those containing cocaine based on the
absence of a carbonyl group in MDMA, which is present in the
chemical structure of cocaine.40
Accordingly, it has been demonstrated the optimum
performance of the selected training set representatives in
accounting for the large structural diversity of NPS and the
subsequent associated ability of the proposed model system to
account for newly emerging architectures.
Conclusions
A three-dimensional model system was successfully demon-
strated for an NPS dataset possessing an inherently large
structural diversity, using Raman spectroscopy with PCA. Due to
this diversity, a systematic optimisation process was required
Fig. 8 Three-dimensional scores plot, Raman spectral proﬁles (grey solid line denotes line loadings plot for PC3) and structures for test set
representatives and associated training set compounds.
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(i.e., spectral pre-processing and reduction of the spectral
range) to achieve the maximum explained variance (37% for the
three rst principal components), whilst retaining model
robustness. The predictive potential was evaluated using both
a validation and a test set, which in all cases these substances
were closely aligned in the three-dimension scores plots with
respect to their structurally related NPS training set. This
demonstrates the utility of combining Raman spectroscopy
(where the signal generated is restricted to Raman active func-
tional groups) with a multivariate approach for model genera-
tion for a structurally diverse dataset. Future work should focus
on implementing models such as these in Raman handheld
instruments for use in-eld. Thus, the results presented herein
will be invaluable to a wide chemistry audience working with
large and structurally complex datasets as well as to the growing
scientic community developing novel identication method-
ologies for NPS and the targeted end-users of this technology
(e.g., health care professionals, law enforcement and border
control).
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